SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-23-084696
Filing Date
2023-03-30
Accepted
2023-03-30 09:25:07
Documents
16

Document Format Files

Seq Description Document Type Size
1 DEF 14A d443897ddef14a.htm   iXBRL DEF 14A 823304
6 GRAPHIC g443897dsp127.jpg GRAPHIC 114156
7 GRAPHIC g443897dsp128.jpg GRAPHIC 124147
  Complete submission text file 0001193125-23-084696.txt   2284550

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA vrml-20221231.xsd EX-101.SCH 5643
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE vrml-20221231_def.xml EX-101.DEF 6156
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE vrml-20221231_lab.xml EX-101.LAB 8401
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vrml-20221231_pre.xml EX-101.PRE 5410
10 EXTRACTED XBRL INSTANCE DOCUMENT d443897ddef14a_htm.xml XML 247200
Mailing Address 12117 BEE CAVES ROAD BUILDING THREE SUITE 100 AUSTIN TX 78738
Business Address 12117 BEE CAVES ROAD BUILDING THREE SUITE 100 AUSTIN TX 78738 512-519-0400
Aspira Women's Health Inc. (Filer) CIK: 0000926617 (see all company filings)

IRS No.: 330595156 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-34810 | Film No.: 23777452
SIC: 2835 In Vitro & In Vivo Diagnostic Substances